We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Expensive generics

14 May 2007 By Una Galani

The US drugs group is paying a hefty E4.9bn for the German unit, thereby leapfrogging rivals into number three spot in the industry. But for the deal to create value, Mylan must deliver its aggressive synergy targets. That won’t be easy.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)